Jazz Pharmaceuticals and Leading Cancer Organizations Collaborate to Launch the First and Only Digital Hub Focused Exclusively on the Emotional, Social and Physical Health Needs of the Small Cell Lung Cancer Community
DUBLIN, June 14, 2021 / PRNewswire / – Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the launch of Nothing Small About It (www.nothingsmallaboutit.com), an online program developed in consultation with cancer organizations from foreground.Care, GO2 Foundation for Lung Cancer, Lung Cancer Foundation of America and LUNGevity Foundation. Nothing Small About It is the first digital hub for the U.S. public dedicated solely to Small Cell Lung Cancer (SCLC) patients and caregivers, and it provides user-friendly content that puts real people and their stories at the center of the story. ‘experience, enabling those living with SCLC to become informed advocates for their health and well-being.
“Our research found that people living with small cell lung cancer and their caregivers tend to feel lost in the larger lung cancer community, and they often experience feelings of stigma, fear and of desperation due to the devastating nature of the disease, ”said Abizer Gaslightwala. , Vice President, US Head of Hematology and Oncology at Jazz Pharmaceuticals. “This idea has led us to collaborate with leading cancer organizations to create a resource that takes into account all the emotional needs of people living with SCPC and their loved ones. That’s why we developed Nothing. Small About It – to humanize the challenges that arise at each stage of diagnosis by increasing awareness of patient and caregiver experiences so that in turn, we can empathize and strengthen feelings of self-worth for people living with the disease – both patients and caregivers. ”
Nothing Small About It takes a user-friendly approach to SCPC awareness by providing patients and caregivers with information to manage SCPC at every stage of diagnosis, while also linking to trusted resources available in the broader cancer community. Thanks to the development and evolution of Nothing Small About It, Jazz aims to provide more personalized support throughout the CPPC continuum of care while inspiring patients and caregivers to take an active role in their health and well-being.
“As rapid and exciting advancements emerge in the treatment of small cell lung cancer, we will work with our partners to put in place substantial resources to help ensure that patients and their caregivers are identified and involved in a coherent and meaningful way ”, declared Laurie Fenton Ambrose, co-founder, president and CEO of the GO2 Foundation. “The different types of support and services will be tailored to better meet people where they are, and Nothing Small About It is a great example of a collaborative initiative that can help stakeholders achieve our common goal of supporting the SCLC community. “
Nothing Small About It greets viewers with an emotionally resonating video titled “Over 10 Minutes,” which allows SCLC patients and their loved ones to hear how others have coped with a diagnosis. progression and other challenges along the way. Viewers then have the opportunity to have an interactive experience that will point them in the right direction for finding resources and support, no matter where they are physically or mentally on their individual cancer journey.
“The most helpful thing for me when I was diagnosed with small cell lung cancer 14 years ago was doing research and trying to get in touch with advocacy groups so that I could inform about my diagnosis, ”said Montessa Lee, an advocate for people living with CPPC and a valued participant in the Nothing Small About It program. “I want other people with small cell lung cancer to know that your life doesn’t end there, and while you may have to go through a journey that can be difficult from time to time, you can go through it with the right support. ”
With unique content suitable for both patients and caregivers, Nothing Small About It allows users to delve deeper into topics such as building a support network, considerations to keep in mind when choosing a a treatment plan and tips for maintaining emotional and physical well-being, among many others.
Nothing Small About It is available to US patients and caregivers who want to learn more about CPPC and how to find help. Visit www.nothingsmallaboutit.com to get started.
About small cell lung cancer
In the United States, about 13 percent of lung cancers are small cell. About 30,000 to 35,000 new cases of small cell lung cancer (SCLC) are reported in the United States each year.1.2 The risk of developing SCLC is much higher in current and former tobacco smokers; However, SCLC can also be caused by exposure to second-hand smoke, asbestos, certain inhaled chemicals, radiation, and air pollution. People with a family history of lung cancer may also be at greater risk.3 SCLC is the most aggressive form of lung cancer and it tends to spread quickly to other parts of the body, including the brain, liver, and bones.4.5 A large percentage of SCLC patients on treatment have a brief response, although the cancer often recurs and is generally more aggressive and resistant to regimens that were previously effective.2
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company dedicated to innovating to transform the lives of patients and their families. We are committed to developing drugs that change the lives of people with serious illnesses – often with limited or no treatment options. We have a diverse portfolio of commercialized drugs and new product candidates, from early to late stage development, in neuroscience and oncology. We are actively exploring new options for patients, including new compounds, small molecules and biologics, as well as through cannabinoid science and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland, and has employees around the world, serving patients in nearly 75 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.
About the GO2 Lung Cancer Foundation
Founded by patients and survivors, GO2 Lung Cancer Foundation transforms survival as the world’s leading organization dedicated to saving, extending and improving the lives of those vulnerable, at risk and diagnosed with lung cancer. The GO2 Foundation serves and listens to people living with and at risk for lung cancer in order to reduce stigma, improve quality of life and increase survival. They empower her community by helping people navigate the pathways of early detection, diagnosis and treatment. The knowledge enables the GO2 Foundation to improve care, amplify awareness, promote advocacy and conduct research with the vision of tripling the number of survivors over the next decade. For more information, visit https://go2foundation.org.
Vice-President, Corporate Affairs
Jazz Pharmaceuticals plc
Ireland, +353 1 697 2141
United States +1 215 867 4910
Andrea N. Flynn, Ph.D.
Vice-President, Head, Investor Relations
Jazz Pharmaceuticals plc
Ireland, +353 1 634 3211
- American Cancer Society. Key statistics for lung cancer. https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html. Update January 12, 2021. Accessed June 11, 2021.
- National Organization for Rare Diseases. Small cell lung cancer. https://rarediseases.org/rare-diseases/small-cell-lung-cancer/. Updated 2019. Accessed June 11, 2021.
- American Cancer Society. Causes of small cell lung cancer, risk factors and prevention. https://www.cancer.org/content/dam/CRC/PDF/Public/8709.00.pdf. Update May 16, 2016. Accessed June 11, 2021.
- American Cancer Society. What is lung cancer? https://www.cancer.org/cancer/lung-cancer/about/what-is.html. Update October 1, 2019. Accessed June 11, 2021.
- American Cancer Society. Stages of small cell lung cancer. https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/staging-sclc.html. Update October 1, 2019. Accessed June 11, 2021.
SOURCE Jazz Pharmaceuticals plc